Intermittent versus Continuous Androgen Suppression Therapy: Do We Have Consensus Yet?
Open Access
- 1 September 2010
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 17 (12) , 45-48
Abstract
Androgen deprivation therapy (ADT) has been a cornerstone in the management of advanced prostate cancer for more than 50 years, but several aspects of the therapy remain controversial. Research since the mid-1980s has looked at the use of intermittent androgen suppression (IAS) as a way to reduce the side effects and costs of continuous androgen suppression. During that same time, testing for prostate-specific antigen resulted in forward stage migration both at diagnosis and at the time of treatment initiation. Earlier treatment has led to prolonged periods of ADT and increasing recognition of the resultant metabolic complications. With preclinical evidence suggesting a potential benefit for IAS in terms of time to androgen independence, with phase II and III studies producing optimistic results, and with the potential for reductions in cost and complications, IAS has become a popular modality of therapy around the globe. Large prospective randomized studies, currently ongoing, will ultimately determine the legitimate place of IAS in the treatment of prostate cancer.Keywords
This publication has 22 references indexed in Scilit:
- Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2010
- Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological GroupEuropean Urology, 2009
- Effect of time of castration and tumour volume on time to androgen‐independent recurrence in Shionogi tumoursBJU International, 2004
- Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility StudyEuropean Urology, 2003
- Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate CancerAmerican Journal of Clinical Oncology, 2003
- Intermittent androgen suppression in patients with prostate cancerBJU International, 2003
- Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateJournal of Urology, 2002
- Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off TherapyThe Oncologist, 2000
- Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.1999
- EFFECTS OF ANDROGEN WITHDRAWAL ON THE STEM-CELL COMPOSITION OF THE SHIONOGI CARCINOMA1990